Literature DB >> 22024054

Bleomycin induced lung fibrosis increases work of breathing in the mouse.

Jonathan E Phillips1, Ruoqi Peng, Lisa Burns, Paul Harris, Rosario Garrido, Gaurav Tyagi, Jay S Fine, Christopher S Stevenson.   

Abstract

Bleomycin induces a transient lung fibrosis in mice that has been used to investigate mechanisms related to idiopathic pulmonary fibrosis. Our aim was to determine a sensitive method for assessing lung function in bleomycin treated mice that correlated with the degree of lung fibrosis as measured by collagen immunohistochemistry. Bleomycin (2 U/kg) or saline was intratracheally microsprayed to male C57BL/6 mice under isoflurane anesthesia. Lung function (single compartment model, constant phase model, and work of breathing) was assessed using the flexiVent system, and after euthanasia lungs were inflated with formalin in situ for histological analysis. The lung fibrosis histopathology score for the bleomycin treated animals on day 21 was indicative of mild-to-moderate fibrosis (Saline treated control: 0 ± 0, Bleomycin treated: 4.9 ± 0.4). There were at least three large areas of fibrosis in the peribronchial alveolar regions of the lung, but less than 50% of each lung was affected by fibrosis. Although changes in lung function were less obvious, volume normalized dynamic work of breathing measured at 30 ml/kg tidal volume (Saline treated control: 9.2 ± 0.1 J/l, Bleomycin treated: 10.6 ± 0.3 J/l) and the oscillatory mechanics constant phase model parameter tissue elastance (H; Saline treated control: 31 ± 2 cm H(2)O/ml, Bleomycin treated: 38 ± 3 cm H(2)O/ml) were significantly increased on day 21. The work of breathing (r = 0.83) correlated slightly better with fibrosis histopathology score than H (r = 0.64). Work of breathing can detect decrements in lung function due to pulmonary fibrosis, correlates well with the amount of collagen in the lungs, and may be a more sensitive quantitative measure of efficacy for drugs being developed to treat pulmonary fibrosis.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22024054     DOI: 10.1016/j.pupt.2011.10.001

Source DB:  PubMed          Journal:  Pulm Pharmacol Ther        ISSN: 1094-5539            Impact factor:   3.410


  11 in total

1.  A carbon nanotube toxicity paradigm driven by mast cells and the IL-₃₃/ST₂ axis.

Authors:  Pranita Katwa; Xiaojia Wang; Rakhee N Urankar; Ramakrishna Podila; Susana C Hilderbrand; Robert B Fick; Apparao M Rao; Pu Chun Ke; Christopher J Wingard; Jared M Brown
Journal:  Small       Date:  2012-07-06       Impact factor: 13.281

Review 2.  Animal models of drug-induced pulmonary fibrosis: an overview of molecular mechanisms and characteristics.

Authors:  Shuchan Li; Jianrong Shi; Huifang Tang
Journal:  Cell Biol Toxicol       Date:  2021-11-05       Impact factor: 6.819

3.  Airway compliance measurements in mouse models of respiratory diseases.

Authors:  Annette Robichaud; Liah Fereydoonzad; Samuel L Collins; Jeffrey Martin Loube; Yumiko Ishii; Maureen R Horton; James G Martin; Wayne Mitzner
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2021-05-19       Impact factor: 6.011

4.  Intratracheal Bleomycin Aerosolization: The Best Route of Administration for a Scalable and Homogeneous Pulmonary Fibrosis Rat Model?

Authors:  Alexandre Robbe; Alexandra Tassin; Justine Carpentier; Anne-Emilie Declèves; Zita Léa Mekinda Ngono; Denis Nonclercq; Alexandre Legrand
Journal:  Biomed Res Int       Date:  2015-05-03       Impact factor: 3.411

5.  Quantification of Pulmonary Fibrosis in a Bleomycin Mouse Model Using Automated Histological Image Analysis.

Authors:  Jean-Claude Gilhodes; Yvon Julé; Sebastian Kreuz; Birgit Stierstorfer; Detlef Stiller; Lutz Wollin
Journal:  PLoS One       Date:  2017-01-20       Impact factor: 3.240

6.  The positive role of vitronectin in radiation induced lung toxicity: the in vitro and in vivo mechanism study.

Authors:  Tian-Le Shen; Mi-Na Liu; Qin Zhang; Wen Feng; Wen Yu; Xiao-Long Fu; Xu-Wei Cai
Journal:  J Transl Med       Date:  2018-04-16       Impact factor: 5.531

7.  Bleomycin induces molecular changes directly relevant to idiopathic pulmonary fibrosis: a model for "active" disease.

Authors:  Ruoqi Peng; Sriram Sridhar; Gaurav Tyagi; Jonathan E Phillips; Rosario Garrido; Paul Harris; Lisa Burns; Lorena Renteria; John Woods; Leena Chen; John Allard; Palanikumar Ravindran; Hans Bitter; Zhenmin Liang; Cory M Hogaboam; Chris Kitson; David C Budd; Jay S Fine; Carla M T Bauer; Christopher S Stevenson
Journal:  PLoS One       Date:  2013-04-02       Impact factor: 3.240

8.  Rupatadine protects against pulmonary fibrosis by attenuating PAF-mediated senescence in rodents.

Authors:  Xiao-xi Lv; Xiao-xing Wang; Ke Li; Zi-yan Wang; Zhe Li; Qi Lv; Xiao-ming Fu; Zhuo-wei Hu
Journal:  PLoS One       Date:  2013-07-15       Impact factor: 3.240

9.  The Influence of BuqiHuoxueTongluo Formula on Histopathology and Pulmonary Function Test in Bleomycin-Induced Idiopathic Pulmonary Fibrosis in Rats.

Authors:  Xiaolin Yu; Yanxia Zhang; Xiaohua Yang; Xiaomei Zhang; Xinxiang Wang; Xuemei Liu; Yan Yan
Journal:  Evid Based Complement Alternat Med       Date:  2018-06-26       Impact factor: 2.629

10.  Fine Particulate Matter-Induced Exacerbation of Allergic Asthma via Activation of T-cell Immunoglobulin and Mucin Domain 1.

Authors:  Yun-Xia Zhao; Hui-Ran Zhang; Xiu-Na Yang; Yu-Hao Zhang; Shan Feng; Feng-Xue Yu; Xi-Xin Yan
Journal:  Chin Med J (Engl)       Date:  2018-10-20       Impact factor: 2.628

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.